Rodolfo Savica, MD, PhD, Mayo Clinic, Rochester, MN, discusses innovative approaches in treating tauopathies by focusing on specific phenotypes. Whilst it is well known the accumulation of certain proteins such as β-amyloid, tau and alpha-synuclein may result in Alzheimer’s disease, progressive supranuclear palsy (PSP) and Parkinson’s disease, respectively, removal of the protein may not necessarily result in improved outcomes. A different approach is consequently required, which involves targeted therapies individualized to the pathology of the patient. This interview took place at the 2022 International Congress of Parkinson’s Disease and Movement Disorders in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.